Empowering Medical Affairs Professionals in Their Critical Role in Integrated Evidence Generation Planning

An integrated evidence generation plan (IEGP) can transform the effectiveness of how pharmaceutical companies demonstrate the value of new therapies. Medical Affairs professionals are uniquely positioned to lead and shape an IEGP, leveraging their scientific and clinical expertise, while maintaining a focus on patient access needs among competing cross-functional priorities. In this article, we explore key subfunctions within Medical Affairs, describing their contributions to the development of an IEGP and discussing the impact of the evolving healthcare environment on their responsibilities. Finally, we consider how to measure the impact of an IEGP for pharmaceutical companies and describe what success looks like for Medical Affairs in the development of an IEGP. Our companion article in this issue of Pharmaceutical Medicine provides more details of the process of integrated evidence generation planning and considers the impact of evolving regulatory and health technology assessment landscapes.

Authors

Institutions

Publication Details

Journal
Pharmaceutical Medicine
Published
2026-08-20
DOI
https://doi.org/10.1007/s40290-026-00625-x
Citations
1
Primary Topic
Health Policy Implementation Science
Type
article
Field-Weighted Citation Impact
13.51
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Empowering Medical Affairs Professionals in Their Critical Role in Integrated Evidence Generation Planning

Judith Nelissen, Cerise James, Gary Male, Angela Williams
1 citations
Pharmaceutical Medicine
Health Policy Implementation Science
13.51
article

Empowering Medical Affairs Professionals in Their Critical Role in Integrated Evidence Generation Planning

Judith Nelissen, Cerise James, Gary Male, Angela Williams
article en
1 citations

Abstract

An integrated evidence generation plan (IEGP) can transform the effectiveness of how pharmaceutical companies demonstrate the value of new therapies. Medical Affairs professionals are uniquely positioned to lead and shape an IEGP, leveraging their scientific and clinical expertise, while maintaining a focus on patient access needs among competing cross-functional priorities. In this article, we explore key subfunctions within Medical Affairs, describing their contributions to the development of an IEGP and discussing the impact of the evolving healthcare environment on their responsibilities. Finally, we consider how to measure the impact of an IEGP for pharmaceutical companies and describe what success looks like for Medical Affairs in the development of an IEGP. Our companion article in this issue of Pharmaceutical Medicine provides more details of the process of integrated evidence generation planning and considers the impact of evolving regulatory and health technology assessment landscapes.

Pharmaceutical Medicine
Oxford Instruments (United Kingdom) (GB), Tilganga Institute of Ophthalmology (NP), Kyowa Kirin International (United Kingdom) (GB), Astellas Pharma (Netherlands) (NL)
Openalex Percentile: Top 1%
Health Policy Implementation Science
13.51
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Empowering Medical Affairs Professionals in Their Critical Role in Integrated Evidence Generation Planning — Judith Nelissen, Cerise James, et al. · Pharmaceutical Medicine (2026) | TGRS Research Map | TGRS